Top Benefits: Enhances weight loss beyond GLP-1 alone Improves insulin response and glucose stability Boosts overall metabolic performance Once-weekly injectable therapy that mimics the natural GLP-1 hormone to improve appetite control and metabolic efficiency
The STEP 1 trial, published in the New England Journal of Medicine, studied once-weekly semaglutide at 2.4mg in adults with overweight or obesity alongside lifestyle intervention
Wojtasiska A, Kumierz J, Tokarek J, Dybiec J, Rodze A, Mynarska E, Rysz J, Franczyk B
An appetite-suppressant in injectable form, semaglutide turns conventional weight loss dogma which demands discipline and sacrifice on its head, seemingly offering a physiological cheat code to those adverse to the old adage eat less and move more
Clark, I